TARSONS Tarsons Products Q3 FY26 results (Oct–Dec 2025) and concall
Tarsons Products reported a strong Q3 FY26 with consolidated revenue growing 12.8% YoY to INR 108 crores and adjusted cash PAT increasing 38.6% YoY to INR 31.4 crores. The company is commercializing its new Panchla facility, with bioprocess products already selling, and anticipates stronger revenue growth from FY27 onwards. Despite facing aggressive pricing in the domestic market and international trade uncertainties, Tarsons expects to benefit from new FTAs and government focus on biopharma.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 12.8%, net profit down 4.2% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 99 | 96 | 113 | 91 | 102 +3% | 108 +13% |
| EBITDA | 25 | 30 | 37 | 25 | 27 +8% | 32 +6% |
| Net profit | 10 | 5 | 10 | 2 | 3 −68% | 5 −4% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
